- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06102148
The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson in Patients With Multiple Sclerosis
October 20, 2023 updated by: Nilay Comuk Balci
The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson Pain, Motor Functions, Fatique and Health Related Quality of Life in Patients With Multiple Sclerosis: A Randomized, Single-blind Study.
The aim of this study is to examine the effects of PNF techniques on pain, motor function, fatigue and quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Samsun, Turkey, 55270
- Ondokuz Mayıs University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- a clinical diagnosis of Relapsing-Remitting MS (RRMS) as defined by McDonald criteria
- 18-65 years of age
- an Expanded Disability Status Scale (EDSS) score < 4
- relapse-free for the last 3 months
- cognitive impairment that was defined with mini mental test.
Exclusion Criteria:
- a history of different neurological diseases
- having any contraindication for exercise
- having orthopedic, vision, hearing, or perception problems.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Control Group
|
Exercise training
|
|
Experimental: PNF Group
|
Exercise training and PNF training
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analogue Scale (VAS)
Time Frame: through study completion, an average of 1 year
|
Pain
|
through study completion, an average of 1 year
|
|
Multiple Sclerosis Quality of Life-54 (MSQoL-54)
Time Frame: through study completion, an average of 1 year
|
Quality of Life
|
through study completion, an average of 1 year
|
|
Fatigue Severity Scale and Fatigue Impact Scale (FIS)
Time Frame: through study completion, an average of 1 year
|
Fatigue
|
through study completion, an average of 1 year
|
|
Timed Up and Go (TUG)
Time Frame: through study completion, an average of 1 year
|
Mobility and Balance
|
through study completion, an average of 1 year
|
|
The Six-Minute Walk Test (6-MWT)
Time Frame: through study completion, an average of 1 year
|
Functionality
|
through study completion, an average of 1 year
|
|
Hand Dexterity
Time Frame: through study completion, an average of 1 year
|
Hand Dexterity
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2021
Primary Completion (Actual)
November 1, 2022
Study Completion (Actual)
November 1, 2022
Study Registration Dates
First Submitted
October 16, 2023
First Submitted That Met QC Criteria
October 20, 2023
First Posted (Actual)
October 26, 2023
Study Record Updates
Last Update Posted (Actual)
October 26, 2023
Last Update Submitted That Met QC Criteria
October 20, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021/413
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on PNF Group
-
Istinye UniversityOndokuz Mayıs UniversityRecruitingHemiplegia | Kinesio Taping | Upper Extremity | Hand Functionality | Hemiplegia Due to Stroke | Proprioceptive Neuromuscular FacilitationTurkey (Türkiye)
-
Jagiellonian UniversityCompletedCervical Spine OsteophytePoland
-
Istanbul UniversityCompletedBronchiectasis | Cystic Fibrosis | Chronic Respiratory DiseaseTurkey
-
Mehmet Hanifi KayaKirsehir Ahi Evran UniversitesiCompleted
-
Superior UniversityCompleted
-
Suleyman Demirel UniversityWithdrawn
-
University of YalovaRecruiting
-
Riphah International UniversityRecruiting
-
University of KarachiCompleted